Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-77242113 in Moderately to Severely Active Ulcerative Colitis
2023-504673-20-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2023
- Modality
- Peptides
- Countries
- 22
01
Overview
Phase 2, randomised, double-blind trial of icotrokinra in autoimmune colitis (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Clinical response at Week 12. Started Nov 2023; status: completed.
02
Drugs
icotrokinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-504673-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504673-20-00.